Literature DB >> 16103173

Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

N A Doria-Rose1, G H Learn, A G Rodrigo, D C Nickle, F Li, M Mahalanabis, M T Hensel, S McLaughlin, P F Edmonson, D Montefiori, S W Barnett, N L Haigwood, J I Mullins.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) is a difficult target for vaccine development, in part because of its ever-expanding genetic diversity and attendant capacity to escape immunologic recognition. Vaccine efficacy might be improved by maximizing immunogen antigenic similarity to viruses likely to be encountered by vaccinees. To this end, we designed a prototype HIV-1 envelope vaccine using a deduced ancestral state for the env gene. The ancestral state reconstruction method was shown to be >95% accurate by computer simulation and 99.8% accurate when estimating the known inoculum used in an experimental infection study in rhesus macaques. Furthermore, the deduced ancestor gene differed from the set of sequences used to derive the ancestor by an average of 12.3%, while these latter sequences were an average of 17.3% different from each other. A full-length ancestral subtype B HIV-1 env gene was constructed and shown to produce a glycoprotein of 160 kDa that bound and fused with cells expressing the HIV-1 coreceptor CCR5. This Env was also functional in a virus pseudotype assay. When either gp160- or gp140-expressing plasmids and recombinant gp120 were used to immunize rabbits in a DNA prime-protein boost regimen, the artificial gene induced immunoglobulin G antibodies capable of weakly neutralizing heterologous primary HIV-1 strains. The results were similar for rabbits immunized in parallel with a natural isolate, HIV-1 SF162. Further design efforts to better present conserved neutralization determinants are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103173      PMCID: PMC1193599          DOI: 10.1128/JVI.79.17.11214-11224.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  HIV sequence databases.

Authors:  Carla Kuiken; Bette Korber; Robert W Shafer
Journal:  AIDS Rev       Date:  2003 Jan-Mar       Impact factor: 2.500

2.  Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.

Authors:  Hua-Xin Liao; S Munir Alam; John R Mascola; James Robinson; Benjiang Ma; David C Montefiori; Maria Rhein; Laura L Sutherland; Richard Scearce; Barton F Haynes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 3.  Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.

Authors:  Jonathan Luke Heeney
Journal:  Expert Rev Vaccines       Date:  2004-08       Impact factor: 5.217

Review 4.  Immunogen sequence: the fourth tier of AIDS vaccine design.

Authors:  James I Mullins; David C Nickle; Laura Heath; Allen G Rodrigo; Gerald H Learn
Journal:  Expert Rev Vaccines       Date:  2004-08       Impact factor: 5.217

Review 5.  HIV-1 prophylactic vaccine trials in Thailand.

Authors:  Punnee Pitisuttithum
Journal:  Curr HIV Res       Date:  2005-01       Impact factor: 1.581

6.  Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses.

Authors:  H Kornfeld; N Riedel; G A Viglianti; V Hirsch; J I Mullins
Journal:  Nature       Date:  1987 Apr 9-15       Impact factor: 49.962

7.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.

Authors:  Feng Gao; Bette T Korber; Eric Weaver; Hua-Xin Liao; Beatrice H Hahn; Barton F Haynes
Journal:  Expert Rev Vaccines       Date:  2004-08       Impact factor: 5.217

Review 9.  HIV vaccine development: lessons from the past and promise for the future.

Authors:  Paul Spearman
Journal:  Curr HIV Res       Date:  2003-01       Impact factor: 1.581

10.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  70 in total

1.  Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Authors:  Nichole Cerutti; Barry V Mendelow; Grant B Napier; Maria A Papathanasopoulos; Mark Killick; Makobetsa Khati; Wendy Stevens; Alexio Capovilla
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Selection on the human immunodeficiency virus type 1 proteome following primary infection.

Authors:  Yi Liu; John McNevin; Jianhong Cao; Hong Zhao; Indira Genowati; Kim Wong; Sherry McLaughlin; Matthew D McSweyn; Kurt Diem; Claire E Stevens; Janine Maenza; Hongxia He; David C Nickle; Daniel Shriner; Sarah E Holte; Ann C Collier; Lawrence Corey; M Juliana McElrath; James I Mullins
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 3.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

4.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

5.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

Review 6.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 7.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.

Authors:  Sampa Santra; Bette T Korber; Mark Muldoon; Dan H Barouch; Gary J Nabel; Feng Gao; Beatrice H Hahn; Barton F Haynes; Norman L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

9.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 10.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.